CRC
SRPT icon

Curi RMB Capital’s Sarepta Therapeutics SRPT Stock Holding History

Curi RMB Capital’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$230K Sell
12,784
-4,856
-28% -$91.8K ﹤0.01% 839
2026
Q1 		$384K Sell
17,640
-1,794
-9% -$34.7K 0.01% 668
2025
Q4 		$418K Buy
+19,434
New +$410K 0.01% 665

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Curi RMB Capital's SRPT Position: Q2 2026 in Review

Curi RMB Capital reduced its Sarepta Therapeutics (SRPT) stake by 28% in Q2 2026, selling an estimated $91.8K and leaving 12,784 shares worth $230K. The position accounts for ﹤0.01% of the portfolio, ranked #839.

Curi RMB Capital first reported a position in SRPT in Q4 2025 and has held it in 3 quarters since. The position peaked at $418K in Q4 2025. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Curi RMB Capital held 12,784 shares of Sarepta Therapeutics worth $230K as of Q2 2026.
  • Curi RMB Capital sold 4,856 Sarepta Therapeutics shares in Q2 2026, an estimated $91.8K.
  • Sarepta Therapeutics made up ﹤0.01% of Curi RMB Capital's portfolio in Q2 2026, its #839 holding.
  • Curi RMB Capital first reported a position in Sarepta Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Curi RMB Capital's Sarepta Therapeutics position peaked at $418K in Q4 2025.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Curi RMB Capital's 13F filing for Q2 2026, filed 14 Aug 2026.